XML 66 R39.htm IDEA: XBRL DOCUMENT v3.25.4
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2025
Fair Value Disclosures [Abstract]  
Summary of Assets and Liabilities That Are Measured at Fair Value on Recurring Basis
The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):
December 31, 2025
TotalLevel 1Level 2Level 3
Assets:
Cash and cash equivalents:
Money market funds$146,136 $146,136 $— $— 
Marketable securities:
Commercial paper4,060 — 4,060 — 
U.S. Treasury securities118,038 118,038 — — 
Corporate bonds114,666 — 114,666 — 
Marketable equity securities18,654 18,654 — — 
Investments:
Synlogic, Inc. warrants (1)
190 — 190 — 
Marketable equity securities1,562 1,562 — — 
Other non-current assets:
Notes receivable7,126 — — 7,126 
Total assets$410,432 $284,390 $118,916 $7,126 
Liabilities:
Accrued expenses and other current liabilities:
Contingent consideration$5,438 $— $— $5,438 
Other non-current liabilities:
Contingent consideration252 — — 252 
Total liabilities$5,690 $— $— $5,690 

December 31, 2024
TotalLevel 1Level 2Level 3
Assets:
Cash and cash equivalents:
Money market funds$521,457 $521,457 $— $— 
Investments:
Synlogic, Inc. warrants (1)
238 — 238 — 
Marketable equity securities17,559 17,559 — — 
Other non-current assets:
Notes receivable14,170 — 12,327 1,843 
Total assets$553,424 $539,016 $12,565 $1,843 
Liabilities:
Accrued expenses and other current liabilities:
Contingent consideration$5,438 $— $— 5,438 
Other non-current liabilities:
Contingent consideration4,484 — — 4,484 
Total liabilities$9,922 $— $— $9,922 
(1)The fair value of Synlogic, Inc. warrants is calculated as the quoted price of the underlying common stock, less the unpaid exercise price of the warrants.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
The table below provides a reconciliation of the beginning and ending balances for assets and liabilities measured at fair value using Level 3 significant unobservable inputs for the years ended December 31 (in thousands):
 Notes ReceivablePrivate Placement WarrantsContingent Consideration
Balance at January 1, 2025$1,843 $— $9,922 
Additions159 — — 
Change in fair value(350)— (4,232)
Settlements and payments(50)— — 
Transfers into Level 36,987 — — 
Conversion to preferred stock(1,463)— — 
Balance at December 31, 2025$7,126 $— $5,690 
Balance at January 1, 2024$14,129 $1,846 $24,273 
Additions1,407 — — 
Change in fair value(3,217)(1,697)3,214 
Settlements and payments— — (17,565)
Transfers to Level 2— (149)— 
Conversion to common stock(10,476)— — 
Balance at December 31, 2024$1,843 $— $9,922 
Summary of Fair Value Measurements Inputs
The following table provides quantitative information regarding Level 3 inputs used in the fair value measurements of contingent consideration liabilities as of the periods presented:
Contingent Consideration LiabilityValuation TechniqueUnobservable InputDecember 31, 2025
Range
December 31, 2024
Range
Earnout payments (FGen and Dutch DNA acquisitions)Probability-weighted present valueProbability of payment
5% - 10%
5% - 50%
Discount rate14.9 %
9.3%
Earnout payments (Dutch DNA acquisition) (1)
Discounted cash flowProjected years of payments
2028-2031
Discount rate10.6 %
(1) During the year ended December 31, 2025, all Dutch DNA milestones valued using the discounted cash flow method were reduced to zero due to the termination of a customer agreement to which those milestones were tied.